Cohance Lifesciences Ltd vs Nectar Lifescience Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Cohance Lifesciences Ltd is ₹ 482.95 as of 30 Apr 15:30 . The P/E Ratio of Cohance Lifesciences Ltd changed from 34.8 on March 2021 to 110.3 on March 2025 . This represents a CAGR of 25.95% over 5 yearsThe P/E Ratio of Nectar Lifescience Ltd changed from 21.5 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 years The Market Cap of Cohance Lifesciences Ltd changed from ₹ 12611 crore on March 2021 to ₹ 29524 crore on March 2025 . This represents a CAGR of 18.55% over 5 yearsThe Market Cap of Nectar Lifescience Ltd changed from ₹ 417.13 crore on March 2021 to ₹ 515.35 crore on March 2025 . This represents a CAGR of 4.32% over 5 years The revenue of Cohance Lifesciences Ltd for the Dec '25 is ₹ 550.71 crore as compare to the Sep '25 revenue of ₹ 571.17 crore. This represent the decline of -3.58% The revenue of Nectar Lifescience Ltd for the Dec '25 is ₹ 88.81 crore as compare to the Sep '25 revenue of ₹ 0.74 crore. This represent the growth of 11901% The ebitda of Cohance Lifesciences Ltd for the Dec '25 is ₹ 96.65 crore as compare to the Sep '25 ebitda of ₹ 136.55 crore. This represent the decline of -29.22% The ebitda of Nectar Lifescience Ltd for the Dec '25 is ₹ 33.53 crore as compare to the Sep '25 ebitda of ₹ -175 crore. This represent the decline of -119% The net profit of Cohance Lifesciences Ltd changed from ₹ 75.37 crore to ₹ 29.02 crore over 7 quarters. This represents a CAGR of -42.04% The net profit of Nectar Lifescience Ltd changed from ₹ 2.97 crore to ₹ 14.27 crore over 7 quarters. This represents a CAGR of 145.20% The Dividend Payout of Cohance Lifesciences Ltd changed from 16.5 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Nectar Lifescience Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Cohance Lifesciences Ltd

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018.
The name of the Company has been changed to Cohance Lifesciences Limited w.e.f.
May 7, 2025.
Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

About Nectar Lifescience Ltd

Nectar Lifescience Limited was initially incorporated on June 27, 1995 as 'Surya Medicare Limited'.
On March 26, 2004, Company changed the name from 'Surya Medicare Limited' to 'Nectar Lifescience Limited'.
NECLIFE is an integrated pharmaceutical organization, engaged in manufacturing and delivering high quality pharmaceutical products.
It is a global pharmaceutical company specializing in Cephalosporins.
Nectar excels in Cephalosporin APIs production with certified facilities meeting global standards.

FAQs for the comparison of Cohance Lifesciences Ltd and Nectar Lifescience Ltd

Which company has a larger market capitalization, Cohance Lifesciences Ltd or Nectar Lifescience Ltd?

Market cap of Cohance Lifesciences Ltd is 18,476 Cr while Market cap of Nectar Lifescience Ltd is 240 Cr

What are the key factors driving the stock performance of Cohance Lifesciences Ltd and Nectar Lifescience Ltd?

The stock performance of Cohance Lifesciences Ltd and Nectar Lifescience Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cohance Lifesciences Ltd and Nectar Lifescience Ltd?

As of May 4, 2026, the Cohance Lifesciences Ltd stock price is INR ₹482.95. On the other hand, Nectar Lifescience Ltd stock price is INR ₹12.4.

How do dividend payouts of Cohance Lifesciences Ltd and Nectar Lifescience Ltd compare?

To compare the dividend payouts of Cohance Lifesciences Ltd and Nectar Lifescience Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.